Aktis Oncology, a US-based clinical-stage biotechnology company discovering and developing novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumours, announced on Thursday the appointment of Ken Herrmann, MD, MBA, to the company's board of directors.

'We are pleased to expand the Aktis board of directors with the appointment of Dr Ken Herrmann, a distinguished figure in the field of oncologic nuclear medicine,' said Matthew Roden, PhD, Aktis Oncology president and chief executive officer. 'Ken's joining us on the board is timely, given the ongoing clinical assessment of our first-in-class Nectin-4-targeted radioconjugate, and I am excited to be able to work with Ken even more closely to achieve Aktis' vision of extending the benefits of radiopharmaceuticals for new patient populations where unmet needs exist.'

The company says that Dr Herrmann is a leader in the field of nuclear medicine with over a decade of experience in clinical investigation, and currently serves as the chair of Aktis' Scientific Advisory Board (SAB). Additionally, Dr Herrmann acts as chair of the Department of Nuclear Medicine at the Universitatsklinikum Essen in Germany, section editor of the Journal of Nuclear Medicine and Cancer Imaging, and until the end of 2023, as chair of the European Association of Nuclear Medicine (EANM) Oncology & Theranostics Committee. He has held the position of vice chair of the Department of Nuclear Medicine at the Universitatsklinikum Wurzburg and served as an associate professor in the Ahmanson Translational Imaging Division at the University of California, Los Angeles. His earlier career achievements include completing his residency in Nuclear Medicine at Klinikum rechts der Isar, Technische Universitat Munchen in addition to his MBA, which he received from the Universitat Zurich, Switzerland in 2011. To date, he has authored over 700 peer-reviewed publications.